These studies reveal that MYCN-amplified (MNA) neuroblastoma is sharply distinguished by the upregulated expression of miRNAs associated with adverse diseases outcome and the downregulation of miRNAs associated with more favorable prognosis. This evidence concerns the gene MYCN and neuroblastoma.